Fasting-mimicking diet and hormone therapy induce breast cancer regression.

Animals Biological Factors / blood Breast Neoplasms / diet therapy Diet Therapy / methods Diet, Healthy / methods Disease Models, Animal Disease Progression Drug Resistance, Neoplasm / drug effects Early Growth Response Protein 1 / metabolism Fasting / physiology Female Fulvestrant / administration & dosage Humans Insulin / blood Insulin-Like Growth Factor I / metabolism Leptin / blood MCF-7 Cells Mice, Inbred NOD Mice, SCID PTEN Phosphohydrolase / metabolism Piperazines / administration & dosage Pyridines / administration & dosage Receptors, Estrogen Receptors, Progesterone Tamoxifen / adverse effects Xenograft Model Antitumor Assays

Journal

Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462

Informations de publication

Date de publication:
07 2020
Historique:
received: 25 11 2018
accepted: 30 04 2020
pubmed: 17 7 2020
medline: 21 10 2020
entrez: 17 7 2020
Statut: ppublish

Résumé

Approximately 75% of all breast cancers express the oestrogen and/or progesterone receptors. Endocrine therapy is usually effective in these hormone-receptor-positive tumours, but primary and acquired resistance limits its long-term benefit

Identifiants

DOI: 10.1038/s41586-020-2502-7 PMID: 32669709 PMC: PMC7881940
pubmed: 32669709
doi: 10.1038/s41586-020-2502-7
pii: 10.1038/s41586-020-2502-7
pmc: PMC7881940
mid: NIHMS1662424
doi:

Substances chimiques

Biological Factors 0
Early Growth Response Protein 1 0
Egr1 protein, mouse 0
Insulin 0
Leptin 0
Piperazines 0
Pyridines 0
Receptors, Estrogen 0
Receptors, Progesterone 0
insulin-like growth factor-1, mouse 0
Tamoxifen 094ZI81Y45
Fulvestrant 22X328QOC4
Insulin-Like Growth Factor I 67763-96-6
PTEN Phosphohydrolase EC 3.1.3.67
Pten protein, mouse EC 3.1.3.67
palbociclib G9ZF61LE7G

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

620-624

Subventions

Organisme : NIA NIH HHS
ID : AG034906
Pays : United States
Organisme : NIA NIH HHS
ID : AG20642
Pays : United States
Organisme : NIA NIH HHS
ID : P01 AG034906
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG020642
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001855
Pays : United States

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : ErratumIn

Références

DeVita, V. J., Laurence, T. S. & Rosenberg, S. A. DeVita, Hellmann and Rosenberg’s Cancer: Principles & Practice of Oncology 11th edn (Wolters Kluwer, 2019).
Araki, K. & Miyoshi, Y. Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer. Breast Cancer 25, 392–401 (2018).
pubmed: 29086897 doi: 10.1007/s12282-017-0812-x
Brandhorst, S. et al. A periodic diet that mimics fasting promotes multi-system regeneration, enhanced cognitive performance, and healthspan. Cell Metab. 22, 86–99 (2015).
pubmed: 26094889 pmcid: 4509734 doi: 10.1016/j.cmet.2015.05.012
Di Biase, S. et al. Fasting-mimicking diet reduces HO-1 to promote T cell-mediated tumor cytotoxicity. Cancer Cell 30, 136–146 (2016).
pubmed: 27411588 pmcid: 5388544 doi: 10.1016/j.ccell.2016.06.005
Wei, M. et al. Fasting-mimicking diet and markers/risk factors for aging, diabetes, cancer, and cardiovascular disease. Sci. Transl. Med. 9, eaai8700 (2017).
pubmed: 28202779 pmcid: 6816332 doi: 10.1126/scitranslmed.aai8700
AlFakeeh, A. & Brezden-Masley, C. Overcoming endocrine resistance in hormone receptor-positive breast cancer. Curr. Oncol. 25, S18–S27 (2018).
pubmed: 29910644 pmcid: 6001756 doi: 10.3747/co.25.3752
Lee, A. V., Cui, X. & Oesterreich, S. Cross-talk among estrogen receptor, epidermal growth factor, and insulin-like growth factor signaling in breast cancer. Clin. Cancer Res. 7, 4429s–4435s (2001).
pubmed: 11916236
Sachs, N. et al. A living biobank of breast cancer organoids captures disease heterogeneity. Cell 172, 373–386 (2018).
pubmed: 29224780 doi: 10.1016/j.cell.2017.11.010
Jones, J. I. & Clemmons, D. R. Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev. 16, 3–34 (1995).
pubmed: 7758431
Garofalo, C., Sisci, D. & Surmacz, E. Leptin interferes with the effects of the antiestrogen ICI 182,780 in MCF-7 breast cancer cells. Clin. Cancer Res. 10, 6466–6475 (2004).
pubmed: 15475434 doi: 10.1158/1078-0432.CCR-04-0203
Sánchez-Jiménez, F., Pérez-Pérez, A., de la Cruz-Merino, L. & Sánchez-Margalet, V. Obesity and breast cancer: role of leptin. Front. Oncol. 9, 596 (2019).
pubmed: 31380268 pmcid: 6657346 doi: 10.3389/fonc.2019.00596
Hopkins, B. D. et al. Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. Nature 560, 499–503 (2018).
pubmed: 30051890 pmcid: 6197057 doi: 10.1038/s41586-018-0343-4
Pollak, M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat. Rev. Cancer 12, 159–169 (2012).
pubmed: 22337149 doi: 10.1038/nrc3215
Jardé, T., Perrier, S., Vasson, M. P. & Caldefie-Chézet, F. Molecular mechanisms of leptin and adiponectin in breast cancer. Eur. J. Cancer 47, 33–43 (2011).
pubmed: 20889333 doi: 10.1016/j.ejca.2010.09.005
Saxena, N. K. et al. Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res. 67, 2497–2507 (2007).
pubmed: 17363567 pmcid: 2925446 doi: 10.1158/0008-5472.CAN-06-3075
Cristofanilli, M. et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 17, 425–439 (2016).
pubmed: 26947331 doi: 10.1016/S1470-2045(15)00613-0
Lasham, A. et al. A novel EGR-1 dependent mechanism for YB-1 modulation of paclitaxel response in a triple negative breast cancer cell line. Int. J. Cancer 139, 1157–1170 (2016).
pubmed: 27072400 doi: 10.1002/ijc.30137
Shajahan-Haq, A. N. et al. EGR1 regulates cellular metabolism and survival in endocrine resistant breast cancer. Oncotarget 8, 96865–96884 (2017).
pubmed: 29228577 pmcid: 5722529 doi: 10.18632/oncotarget.18292
Di Biase, S. et al. Fasting regulates EGR1 and protects from glucose- and dexamethasone-dependent sensitization to chemotherapy. PLoS Biol. 15, e2001951 (2017).
pubmed: 28358805 pmcid: 5373519 doi: 10.1371/journal.pbio.2001951
Di Leva, G. et al. Estrogen mediated-activation of miR-191/425 cluster modulates tumorigenicity of breast cancer cells depending on estrogen receptor status. PLoS Genet. 9, e1003311 (2013).
pubmed: 23505378 pmcid: 3591271 doi: 10.1371/journal.pgen.1003311
Hawley, S. A. et al. Phosphorylation by Akt within the ST loop of AMPK-α1 down-regulates its activation in tumour cells. Biochem. J. 459, 275–287 (2014).
pubmed: 24467442 doi: 10.1042/BJ20131344
Arends, J. et al. ESPEN guidelines on nutrition in cancer patients. Clin. Nutr. 36, 11–48 (2017).
pubmed: 27637832 doi: 10.1016/j.clnu.2016.07.015
Grundmann, O., Yoon, S. L. & Williams, J. J. The value of bioelectrical impedance analysis and phase angle in the evaluation of malnutrition and quality of life in cancer patients—a comprehensive review. Eur. J. Clin. Nutr. 69, 1290–1297 (2015).
pubmed: 26220573 doi: 10.1038/ejcn.2015.126
Turner, N. C. et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 373, 209–219 (2015).
pubmed: 26030518 doi: 10.1056/NEJMoa1505270
Creighton, C. J. et al. Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J. Clin. Oncol. 26, 4078–4085 (2008).
pubmed: 18757322 pmcid: 2654368 doi: 10.1200/JCO.2007.13.4429
Karey, K. P. & Sirbasku, D. A. Differential responsiveness of human breast cancer cell lines MCF-7 and T47D to growth factors and 17 beta-estradiol. Cancer Res. 48, 4083–4092 (1988).
pubmed: 3289739
Baselga, J. et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 366, 520–529 (2012).
pubmed: 22149876 doi: 10.1056/NEJMoa1109653
André, F. et al. Alpelisib for PIK3CA-Mutated, hormone receptor-positive advanced breast cancer. N. Engl. J. Med. 380, 1929–1940 (2019).
pubmed: 31091374 doi: 10.1056/NEJMoa1813904
Hu, R., Hilakivi-Clarke, L. & Clarke, R. Molecular mechanisms of tamoxifen-associated endometrial cancer (Review). Oncol. Lett. 9, 1495–1501 (2015).
pubmed: 25788989 pmcid: 4356269 doi: 10.3892/ol.2015.2962
Piacente, F. et al. Nicotinic acid phosphoribosyltransferase regulates cancer cell metabolism, susceptibility to NAMPT inhibitors, and DNA repair. Cancer Res. 77, 3857–3869 (2017).
pubmed: 28507103 doi: 10.1158/0008-5472.CAN-16-3079
Caffa, I. et al. Fasting potentiates the anticancer activity of tyrosine kinase inhibitors by strengthening MAPK signaling inhibition. Oncotarget 6, 11820–11832 (2015).
pubmed: 25909220 pmcid: 4494907 doi: 10.18632/oncotarget.3689
Ciribilli, Y. et al. The coordinated p53 and estrogen receptor cis-regulation at an FLT1 promoter SNP is specific to genotoxic stress and estrogenic compound. PLoS One 5, e10236 (2010).
pubmed: 20422012 pmcid: 2858160 doi: 10.1371/journal.pone.0010236
Liu, C. Y. et al. Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A-dependent phospho-Akt inactivation in estrogen receptor-negative human breast cancer cells. Breast Cancer Res. 16, 431 (2014).
pubmed: 25228280 pmcid: 4303112 doi: 10.1186/s13058-014-0431-9
Massarweh, S. et al. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res. 68, 826–833 (2008).
pubmed: 18245484 doi: 10.1158/0008-5472.CAN-07-2707
Mishra, A. K., Abrahamsson, A. & Dabrosin, C. Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ. Oncotarget 7, 56876–56888 (2016).
pubmed: 27486755 pmcid: 5302959 doi: 10.18632/oncotarget.10871
Ikeda, H. et al. Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer. Cancer Sci. 102, 2038–2042 (2011).
pubmed: 21801281 doi: 10.1111/j.1349-7006.2011.02050.x
Massarweh, S. et al. Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer. Cancer Res. 66, 8266–8273 (2006).
pubmed: 16912207 doi: 10.1158/0008-5472.CAN-05-4045
Vijayaraghavan, S. et al. CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers. Nat. Commun. 8, 15916 (2017).
pubmed: 28653662 pmcid: 5490269 doi: 10.1038/ncomms15916
Cook Sangar, M. L. et al. Inhibition of CDK4/6 by palbociclib significantly extends survival in medulloblastoma patient-derived xenograft mouse models. Clin. Cancer Res. 23, 5802–5813 (2017).
pubmed: 28637687 pmcid: 6939669 doi: 10.1158/1078-0432.CCR-16-2943
Michaloglou, C. et al. Combined inhibition of mTOR and CDK4/6 is required for optimal blockade of E2F function and long-term growth inhibition in estrogen receptor-positive breast cancer. Mol. Cancer Ther. 17, 908–920 (2018).
pubmed: 29483206 pmcid: 6485624 doi: 10.1158/1535-7163.MCT-17-0537
Lee, C. et al. Reduced levels of IGF-I mediate differential protection of normal and cancer cells in response to fasting and improve chemotherapeutic index. Cancer Res. 70, 1564–1572 (2010).
pubmed: 20145127 pmcid: 2836202 doi: 10.1158/0008-5472.CAN-09-3228
Ahima, R. S. et al. Role of leptin in the neuroendocrine response to fasting. Nature 382, 250–252 (1996).
pubmed: 8717038 doi: 10.1038/382250a0
Lee, C. et al. Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Sci. Transl. Med. 4, 124ra27 (2012).
pubmed: 22323820 pmcid: 3608686 doi: 10.1126/scitranslmed.3003293
Arends, J. et al. ESPEN expert group recommendations for action against cancer-related malnutrition. Clin. Nutr. 36, 1187–1196 (2017).
pubmed: 28689670 doi: 10.1016/j.clnu.2017.06.017
Reidy, P. T. et al. Protein blend ingestion following resistance exercise promotes human muscle protein synthesis. J. Nutr. 143, 410–416 (2013).
pubmed: 23343671 pmcid: 3738242 doi: 10.3945/jn.112.168021
Rossi, F., Valdora, F., Barabino, E., Calabrese, M. & Tagliafico, A. S. Muscle mass estimation on breast magnetic resonance imaging in breast cancer patients: comparison between psoas muscle area on computer tomography and pectoralis muscle area on MRI. Eur. Radiol. 29, 494–500 (2019).
pubmed: 30088069 doi: 10.1007/s00330-018-5663-0

Auteurs

Irene Caffa (I)

IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

Vanessa Spagnolo (V)

Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
IFOM, FIRC Institute of Molecular Oncology, Milan, Italy.

Claudio Vernieri (C)

IFOM, FIRC Institute of Molecular Oncology, Milan, Italy.
Medical Oncology and Hematology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Francesca Valdemarin (F)

IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy.

Pamela Becherini (P)

IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy.

Min Wei (M)

Longevity Institute, Leonard Davis School of Gerontology and Department of Biological Sciences, University of Southern California, Los Angeles, CA, USA.

Sebastian Brandhorst (S)

Longevity Institute, Leonard Davis School of Gerontology and Department of Biological Sciences, University of Southern California, Los Angeles, CA, USA.

Chiara Zucal (C)

Department of Cellular, Computational, and Integrative Biology (CIBIO), University of Trento, Trento, Italy.

Else Driehuis (E)

Oncode Institute and Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences, Utrecht, The Netherlands.
University Medical Center Utrecht, Utrecht, The Netherlands.

Lorenzo Ferrando (L)

Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy.
ORCID: 0000-0002-4025-7930

Francesco Piacente (F)

IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy.

Alberto Tagliafico (A)

Department of Health Sciences, University of Genoa, Genoa, Italy.

Michele Cilli (M)

IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

Luca Mastracci (L)

IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Department of Integrated Surgical and Diagnostic Sciences, University of Genoa, Genoa, Italy.

Valerio G Vellone (VG)

IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Department of Integrated Surgical and Diagnostic Sciences, University of Genoa, Genoa, Italy.

Silvano Piazza (S)

Department of Cellular, Computational, and Integrative Biology (CIBIO), University of Trento, Trento, Italy.
ORCID: 0000-0002-7156-5434

Anna Laura Cremonini (AL)

IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy.

Raffaella Gradaschi (R)

IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

Carolina Mantero (C)

IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

Mario Passalacqua (M)

Department of Experimental Medicine, University of Genoa, Genoa, Italy.
ORCID: 0000-0003-2779-6259

Alberto Ballestrero (A)

IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy.

Gabriele Zoppoli (G)

IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy.

Michele Cea (M)

IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy.
ORCID: 0000-0003-3345-0799

Annalisa Arrighi (A)

Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy.

Patrizio Odetti (P)

IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy.

Fiammetta Monacelli (F)

IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy.

Giulia Salvadori (G)

Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
IFOM, FIRC Institute of Molecular Oncology, Milan, Italy.
ORCID: 0000-0001-5175-2868

Salvatore Cortellino (S)

IFOM, FIRC Institute of Molecular Oncology, Milan, Italy.

Hans Clevers (H)

Oncode Institute and Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences, Utrecht, The Netherlands.
University Medical Center Utrecht, Utrecht, The Netherlands.
Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.
ORCID: 0000-0002-3077-5582

Filippo De Braud (F)

Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
Medical Oncology and Hematology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Samir G Sukkar (SG)

IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

Alessandro Provenzani (A)

Department of Cellular, Computational, and Integrative Biology (CIBIO), University of Trento, Trento, Italy.

Valter D Longo (VD)

IFOM, FIRC Institute of Molecular Oncology, Milan, Italy. vlongo@usc.edu.
Longevity Institute, Leonard Davis School of Gerontology and Department of Biological Sciences, University of Southern California, Los Angeles, CA, USA. vlongo@usc.edu.
ORCID: 0000-0002-0946-7534

Alessio Nencioni (A)

IRCCS Ospedale Policlinico San Martino, Genoa, Italy. alessio.nencioni@unige.it.
Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy. alessio.nencioni@unige.it.
ORCID: 0000-0001-5068-8884

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Fasting-mimicking diet and hormone therapy...
questionsmedicales.fr › Facteurs biologiques › Fasting-mimicking diet and hormone therapy...
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Maladies du sein › Tumeurs du sein › Fasting-mimicking diet and hormone therapy...
questionsmedicales.fr › Thérapeutique › Thérapie nutritionnelle › Diétothérapie › Fasting-mimicking diet and hormone therapy...
questionsmedicales.fr › Phénomènes physiologiques › Alimentation et nutrition › Phénomènes physiologiques nutritionnels › Régime alimentaire › Régime alimentaire sain › Fasting-mimicking diet and hormone therapy...
questionsmedicales.fr › Techniques d'investigation › Modèles théoriques › Modèles biologiques › Modèles animaux de maladie humaine › Fasting-mimicking diet and hormone therapy...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Évolution de la maladie › Fasting-mimicking diet and hormone therapy...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Résistance aux substances › Résistance aux médicaments antinéoplasiques › Fasting-mimicking diet and hormone therapy...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Facteurs de transcription › Facteurs de transcription EGR › Facteur de transcription EGR-1 › Fasting-mimicking diet and hormone therapy...
questionsmedicales.fr › Phénomènes physiologiques › Alimentation et nutrition › Phénomènes physiologiques nutritionnels › Comportement alimentaire › Jeûne › Fasting-mimicking diet and hormone therapy...
questionsmedicales.fr › Hormones gonadiques › Hormones sexuelles stéroïdiennes › Congénères de l'oestradiol › Oestradiol › Fulvestrant › Fasting-mimicking diet and hormone therapy...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Fasting-mimicking diet and hormone therapy...
questionsmedicales.fr › Acides aminés, peptides et protéines › Peptides › Hormones peptidiques › Hormones pancréatiques › Insulines › Insuline › Fasting-mimicking diet and hormone therapy...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Somatomédines › Facteur de croissance IGF-I › Fasting-mimicking diet and hormone therapy...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Adipokines › Leptine › Fasting-mimicking diet and hormone therapy...
questionsmedicales.fr › Cellules › Cellules cultivées › Lignée cellulaire › Cellules MCF-7 › Fasting-mimicking diet and hormone therapy...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Lignées consanguines de souris › Souris de lignée NOD › Fasting-mimicking diet and hormone therapy...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Souches mutantes de souris › Souris SCID › Fasting-mimicking diet and hormone therapy...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines tumorales › Protéines suppresseurs de tumeurs › Phosphohydrolase PTEN › Fasting-mimicking diet and hormone therapy...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pipérazines › Fasting-mimicking diet and hormone therapy...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyridines › Fasting-mimicking diet and hormone therapy...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Facteurs de transcription › Récepteurs aux stéroïdes › Récepteurs des oestrogènes › Fasting-mimicking diet and hormone therapy...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Récepteurs cytoplasmiques et nucléaires › Récepteurs à la progestérone › Fasting-mimicking diet and hormone therapy...
questionsmedicales.fr › Composés chimiques organiques › Hydrocarbures › Hydrocarbures cycliques › Hydrocarbures aromatiques › Dérivés du benzène › Composés benzylidéniques › Stilbènes › Tamoxifène › Fasting-mimicking diet and hormone therapy...
questionsmedicales.fr › Techniques d'investigation › Transplantation tumorale › Tests d'activité antitumorale sur modèle de xénogreffe › Fasting-mimicking diet and hormone therapy...